ClinicalTrials.gov
ClinicalTrials.gov Menu

30Gy Versus 40Gy Involved-field Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01156259
Recruitment Status : Unknown
Verified April 2010 by Chinese Academy of Medical Sciences.
Recruitment status was:  Recruiting
First Posted : July 2, 2010
Last Update Posted : July 2, 2010
Sponsor:
Collaborator:
Sun Yat-sen University
Information provided by:
Chinese Academy of Medical Sciences

Brief Summary:
The purpose of this study is to determine whether 30Gy Involved-field Radiotherapy (IFRT) is as effective as 40Gy in the treatment of localized Diffused Large B cell Lymphoma (DLBCL) when completing CR after chemotherapy.

Condition or disease Intervention/treatment Phase
Lymphoma, Large B-Cell, Diffuse Radiation: 3D-CRT based Involved Field Radiotherapy Phase 3

Detailed Description:
The best proper doses of IFRT in combined modality treatments (CMT) for localized DLBCL is still undetermined. Existing treatment guidelines recommend 40Gy or above as the standard treatment dosage. However, there were large-scaled clinical trials implying smaller doses such as 30Gy may be equivalent effective. Lowering radiation doses can decrease treatment toxicities and radiotherapy-induced diseases, which has been conformed by HD13 study for Hodgkin's Lymphoma. It may even retain the truth when modern era radiation techniques are involved and especially in patients achieving CR after chemotherapy. A comprehensive, prospective dose-comparing study is needed.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 400 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 3 Study of 30Gy Versus 40Gy Involved-field Radiotherapy in Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy
Study Start Date : April 2010
Estimated Primary Completion Date : April 2015
Estimated Study Completion Date : May 2015


Arm Intervention/treatment
Experimental: 30 Gy Radiation: 3D-CRT based Involved Field Radiotherapy
CT simulation, 3D-CRT or IMRT techniques, Involved Field Radiotherapy of 30Gy

Active Comparator: 40 Gy Radiation: 3D-CRT based Involved Field Radiotherapy
CT simulation, 3D-CRT or IMRT techniques, Involved Field Radiotherapy of 40Gy




Primary Outcome Measures :
  1. disease free survival [ Time Frame: five years ]

Secondary Outcome Measures :
  1. overall survival [ Time Frame: five years ]
  2. acute treatment toxicity [ Time Frame: up to 16 weeks ]
  3. late treatment toxicity [ Time Frame: five years ]
  4. treatment failure type [ Time Frame: five years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   15 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • biopsy-proved Diffuse Large B cell lymphoma
  • nonbulky stage I, nonbulky stage IE, nonbulky stage II, or nonbulky stage IIE disease(Bulky disease was defined as a mass 10 cm or more in maximal diameter) according to Ann Arbor Staging
  • provide written informed consent
  • Complete regression after chemotherapy
  • Considerable to CT simulation and 3D CRT or IMRT
  • Performance status 0-2 WHO criteria;life expectation>6 months
  • negative for human immunodeficiency virus syndrome (HIV)
  • Minimal staging included chest radiograph, computed tomography of the abdomen and pelvis, and single percutaneous bone marrow biopsy and blood studies

Exclusion Criteria:

  • primary mediastinal large B cell lymphoma
  • dermatological lymphoma
  • testicular lymphoma
  • primary central nerve system lymphoma
  • prior RT
  • history of low-grade lymphoma congestive
  • history of heart failure (CHF; New York Heart Association [NYHA] classifications III-IV), history of neoplasm (adequately treated basal cell carcinoma of the skin or in situ carcinoma of the uterine cervix were allowed), abnormal liver function tests (aminotransferases and alkaline phosphatase > 2.5 times the upper limit of normal, bilirubin > 50 ), renal insufficiency (serum creatinine > 300 ), and patients with any serious medical or psychiatric illness that would prevent informed consent or completion of protocol-prescribed treatment and follow-up

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01156259


Contacts
Contact: YeXiong Li, MD 8610-87788860 yexiong3@yahoo.com.cn
Contact: Shunan Qi, MD 8610-87725547 qishunan@yahoo.cn

Locations
China, Beijing
Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Recruiting
Beijing, Beijing, China, 100021
Contact: Shunan qi, MD    8610-87725547    qishunan@yahoo.cn   
Sponsors and Collaborators
Chinese Academy of Medical Sciences
Sun Yat-sen University
Investigators
Study Director: Yexiong Li, MD Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Responsible Party: Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
ClinicalTrials.gov Identifier: NCT01156259     History of Changes
Other Study ID Numbers: CH-LYM-004
First Posted: July 2, 2010    Key Record Dates
Last Update Posted: July 2, 2010
Last Verified: April 2010

Keywords provided by Chinese Academy of Medical Sciences:
B cell cll/lymphoma, human

Additional relevant MeSH terms:
Lymphoma
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin